🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07233746
Starting soon Not applicable

Comparison of QIPB and SIFICB in Hip Surgery

NCT07233746 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-12-15
Last updated
2025-11-18

Condition(s) studied

Postoperative PainHip Surgery

Investigational drug(s) / intervention(s)

Quadro-İliac Plane Block(QİPB)Suprainguinal Fascia Iliaca Compartiment Block

Quadro-İliac Plane Block(QİPB): 40 mL of 0.25% bupivacaine

Suprainguinal Fascia Iliaca Compartiment Block: 30 mL of 0.25% bupivacaine

Study summary

The aim is to compare the postoperative analgesic effects of Quadroiliac Plane Block (QIPB) and Suprainguinal Fascia Iliaca Compartment Block (SIFICB) in patients undergoing hip surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients over 18 years of age who underwent percutaneous nephrolithotomy under general anesthesia and were I-II-III according to the American Society of Anesthesiologists (ASA) risk classification were included in the study. Exclusion Criteria: * patients who did not give consent, * patients with coagulopathy, * patients with signs of infection at the block application site, * patients using anticoagulants, * patients with known allergies to any of the study drugs, * patients with unstable hemodynamics, * patients who could not cooperate during postoperative pain assessment * patients who wanted to withdraw from the study, * patients with alcohol and drug addiction, * patients with musculoskeletal abnormalitie

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sivas Cumhuriyet University School of Medicine, Anesthesiology and Reanimation Sivas Sivas

More Cumhuriyet University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07233746 on ClinicalTrials.gov ↗ ← All trials in Turkey